

Enhancing ADR Detection through GNNs and DDIs

Mr. N. Yuvaraj¹, Mr. Pkrishnakishore², Mr. P Soma Sekhar³, Mr. K Chandu⁴

Assistant Professor, Computer Science and Engineering¹

Students, Computer Science and Engineering^{2,3,4}

Dhanalakshmi College of Engineering, Chennai, Tamil Nadu

Abstract: Adverse Drug Reactions (ADRs) caused by Drug-Drug Interactions (DDIs) pose a critical challenge in pharmacovigilance. This paper presents a deep learning-based system employing Graph Neural Networks (GNNs) and Self-Supervised Learning to effectively predict ADRs. By modeling drug interactions from DrugBank using SMILES-based molecular fingerprints and incorporating a Variational Autoencoder (VAE), the system achieves an accuracy of 97.69%. Comparative evaluations with K-Nearest Neighbors (KNN), Decision Trees, and 2D Convolutional Neural Networks (CNN2D) reveal the superior performance of deep learning methods. This work demonstrates the potential of GNNs in proactive ADR detection to enhance drug safety.

Keywords: 5G Signal Forecasting, Machine Learning Models, RF Signal Analysis, Stacking Ensemble, Voting Ensemble, Convolutional Neural Network, Feature Importance, Predictive Accuracy, Network Performance, Ensemble Learning

I. INTRODUCTION

An Adverse Drug Reaction (ADR) can be defined as a significantly harmful or unpleasant reaction usually attributed to the use of medicines and may warrant treatment, prevention, alteration of dosage, or withdrawal of the usage of that drug. They are a major threat to the healthcare system since they contribute to mortality, morbidity, extended hospital stays, and increased healthcare costs. Many of the side effects are not observed during clinical trials but are mostly identified only after the drug has reached the market. Several studies also show that reports of Adverse Drug Reactions tend to be skewed based on sex, geographic region of origin, and country of origin. For instance, according to, women are at more risk of adverse drug reactions due to differences in pharmacokinetic and pharmacodynamic effects of drugs in addition to their higher dosage concerning body weight. Further, factors such as access to healthcare based on country of residence and their healthcare quality play a role as well. According to, the median proportion of preventable ADRs in developed and developing countries is 71.6% and 59.6% respectively, and the median proportions of ADRs relating in mortality were 1.7% and 1.8% in developed and developing countries respectively. The majority of these ADRs were preventable in both situations signifying the importance of early prediction of such ADRs and improving medical use in developing countries.

Objective

The objective of this study is to develop a robust methodology for predicting Adverse Drug Reactions (ADRs) stemming from drug-drug interactions. By employing a combination of algorithms, including K-Nearest Neighbors (KNN), Decision Trees, a Graph Neural Network (GNN), and a twodimensional Convolutional Neural Network (CNN2D), the research aims to accurately identify potential side effects before drug market release. This approach seeks to enhance the detection of ADRs, addressing the critical public health issue associated with complex drug interactions.

II. LITERATURE SURVEY

[1] Title: "SSF-DDI: a deep learning method utilizing drug sequence and substructure features for drug-drug interaction prediction"



ABSTRACT: Background Drug–drug interactions (DDI) are prevalent in combination therapy, necessitating the importance of identifying and predicting potential DDI. While various artificial intelligence methods can predict and identify potential DDI, they often overlook the sequence information of drug molecules and fail to comprehensively consider the contribution of molecular substructures to DDI. Results In this paper, we proposed a novel model for DDI prediction based on sequence and substructure features (SSF-DDI) to address these issues. Our model integrates drug sequence features and structural features from the drug molecule graph, providing enhanced information for DDI prediction and enabling a more comprehensive and accurate representation of drug molecules. Conclusion The results of experiments and case studies have demonstrated that SSF-DDI significantly outperforms state-of-the-art DDI prediction models across multiple real datasets and settings. SSF-DDI performs better in predicting DDI involving unknown drugs, resulting in a 5.67% improvement in accuracy compared to state-of-the-art methods

[2] Title: “Explainable Drug Repurposing Approach from Biased Random Walks”

ABSTRACT: Drug repurposing is a highly active research area, aiming at finding novel uses for drugs that have been previously developed for other therapeutic purposes. Despite the flourishing of methodologies, success is still partial, and different approaches offer, each, peculiar advantages. In this composite landscape, we present a novel methodology focusing on an efficient mathematical procedure based on gene similarity scores and biased random walks which rely on robust drug-gene-disease association data sets. The recommendation mechanism is further unveiled by means of the Markov chain underlying the random walk process, hence providing explainability about how findings are suggested. Performances evaluation and the analysis of a case study on rheumatoid arthritis show that our approach is accurate in providing useful recommendations and is computationally efficient, compared to the state of the art of drug repurposing approaches.

III. EXISTING SYSTEM

This uses machine learning and neural networks to help discover new medicines. It looks at data from cells and drugs to find how well a drug might work. The system fills in missing values (like IC50) using smart algorithms. It compares drug pairs based on how they act, what they treat, their chemical makeup, and their genes. Simple models like Naive Bayes and Decision Tree help make these predictions. A new method first filters the good data, then uses LSTM to analyze it better. Another method studies how proteins interact to improve drug understanding. All this helps in finding better and faster ways to develop medicine.

Disadvantages

The current system focuses more on how well a drug works, not on side effects, which can be risky for patients.

- It uses older machine learning methods that may not understand complex drug relationships very well.
- It doesn't use new self-learning methods that could help the system learn better from data without labels, making predictions more accurate.

Proposed System

The new system uses smart machine learning to predict harmful side effects when two or more drugs interact. It uses a Graph Neural Network (GNN) to understand drug relationships by looking at their chemical structures. A special autoencoder helps the system learn better without needing labeled data. It also includes basic models like KNN and Decision Trees to compare results. A 2D CNN is added to find more detailed features from the data. This combined method helps doctors find risky drug combinations and keep patients safer.

Advantages

It uses GNN to understand complex drug relationships better, helping predict harmful side effects more accurately.

- A special learning layer (autoencoder) improves model training and avoids overfitting, making predictions more reliable.



- It mixes advanced (like CNN) and traditional methods (like KNN, Decision Tree) to compare and improve the results, helping doctors make safer decisions.

Modules

DATA HANDLING AND PREPARATION:

This part includes Data Loading, Visualization, and Data Pre-processing. The dataset is first loaded into the system, where a graph is then used to visually represent different side effects by showing their frequency. After visualization, the data undergoes preprocessing, where drug information is transformed into numerical vectors for analysis and model training.

TEXT VECTORIZATION AND DATA SPLITTING: TFIDF

Vectorization is used to convert the textual drug data into a numerical format by analyzing the importance of terms in the context of the dataset. This ensures that meaningful words are highlighted while common words are minimized. After vectorization, the data is split into training and testing sets, which is essential for training models and evaluating their accuracy.

MODEL DEVELOPMENT AND EVALUATION:

In the Model Generation module, multiple algorithms are trained and evaluated. This includes traditional models like K-Nearest Neighbours (KNN) and Decision Tree, as well as advanced models like the proposed Graph Neural Network (GNN) and extended CNN2D. The system compares their performance using standard evaluation metrics to determine the most accurate model.

PREDICTION AND USER INTERACTION

Once the models are trained, users can interact with the system by uploading test data for Drug Side Effect Prediction. The system then processes this input and provides the final prediction result, helping users identify potential drug side effects based on the trained models.

IV. CONCLUSION

The critical need for an efficient and reliable method to predict Adverse Drug Reactions (ADRs) stemming from drug-drug interactions, a significant public health issue. Current detection methods often fall short, relying heavily on post-marketing reports and failing to identify rare interactions before drug release. Our proposed system, utilizing a Graph Neural Network (GNN) combined with Self-Supervised Learning, demonstrates a robust capability to predict potential ADRs accurately. The GNN effectively models the relationships between drugs, significantly enhancing the prediction process by capturing the complex interactions that can lead to adverse reactions. With an impressive accuracy of 97.69%, the GNN outperforms traditional algorithms, showcasing its effectiveness in identifying harmful drug combinations. Additionally, incorporating advanced methodologies, such as a two-dimensional Convolutional Neural Network (CNN2D), further elevates performance, achieving an outstanding accuracy of 99.87%. This study underscores the potential of employing cutting-edge machine learning techniques to improve drug safety and patient outcomes, ultimately contributing to more informed healthcare practices and reducing the incidence of ADRs.

Future Enhancement

This project includes exploring the integration of advanced techniques such as ensemble learning, reinforcement learning, and transfer learning to enhance predictive accuracy and model robustness. Additionally, incorporating more diverse datasets and utilizing unsupervised learning methods could improve the system's ability to identify complex drug-drug interactions. Investigating the application of explainable AI techniques will also be vital in providing insights into the model's decision-making process, fostering trust and understanding among healthcare professional.



REFERENCES

- [1] J. Zhu, C. Che, H. Jiang, J. Xu, J. Yin, and Z. Zhong, "SSF-DDI: A deep learning method utilizing drug sequence and substructure features for drug–drug interaction prediction," *BMC Bioinf.*, vol. 25, no. 1, p. 39, Jan. 2024
- [2] P. Bongini, F. Scarselli, M. Bianchini, G. M. Dimitri, N. Pancino, and P. Lió, "Modular multi–source prediction of drug side–effects with DruGNN," *IEEE/ACM Trans. Comput. Biol. Bioinf.*, vol. 20, no. 2, pp. 1211–1220, Mar. 2023.
- [3] F. Castiglione, C. Nardini, E. Onofri, M. Pedicini, and P. Tieri, "Explainable drug repurposing approach from biased random walks," *IEEE/ACM Trans. Comput. Biol. Bioinf.*, vol. 20, no. 2, pp. 1009–1019, Mar. 2023.
- [4] S. Abbas, G. Avelino Sampedro, M. Abisado, A. S. Almadhor, T.-H. Kim, and M. Mohamed Zaidi, "A novel drug–drug indicator dataset and ensemble stacking model for detection and classification of drug–drug interaction indicators," *IEEE Access*, vol. 11, pp. 101525–101536, 2023.
- [5] J. Zhang and M. Xie, "NNDSVD-GRMF: A graph dual regularization matrix factorization method using non-negative initialization for predicting drug–target interactions," *IEEE Access*, vol. 10, pp. 91235–91244, 2022.
- [6] C. Kim and N. Tatonetti, "Prediction of adverse drug reactions associated with drug–drug interactions using hierarchical classification," *bioRxiv*, Feb. 2021.
- [7] C. Palleria, A. Di Paolo, C. Giofrè, C. Caglioti, G. Leuzzi, A. Siniscalchi, G. De Sarro, and L. Gallelli, "Pharmacokinetic drug–drug interaction and their implication in clinical management," *J. Res. Med. Sciences*, vol. 18, no. 7, p. 601, 2013.
- [8] F. Del Pup and M. Atzori, "Applications of self-supervised learning to biomedical signals: A survey," *IEEE Access*, vol. 11, pp. 144180–144203, 2023.

